We are thrilled to congratulate all the NeoVanc Investigators and Co-Investigators for having reached (and exceeded) the important milestone of 100 children enrolled!
The effort they have put so far in the NeoVanc project has been essential in accomplishing this significant achievement!! Thank you to all of them!
One-third of the recruitment is complete!
With new sites opening soon and with the Investigators and Co-Investigators ongoing dedication and commitment, the NeoVanc team is confident recruitment will speed up and the target of 300 infants will be hit soon!
NeoVanc is funded by the European Commission under the Seventh Framework Programme for research, technological development and demonstration. The aim is to develop an optimal dosing and monitoring regimen for vancomycin use in preterm neonates and infants under 3 months of age and subsequently conduct a randomised clinical trial with PK/PD targets as the primary outcome.